Mastering the Art of Topical Drug Delivery: Best Practices in Formulation Development for Enhanced Skin Penetration

Defining Enhanced Skin Penetration in Topical Formulation Development

Achieving enhanced skin penetration is a primary goal in topical drug delivery, where the intent is to deliver active pharmaceutical ingredients (APIs) locally or systemically through the skin barrier. For pharmaceutical, biotech, and formulation scientists, the focus is not simply on API application to the skin, but on optimizing formulation variables to improve topical drug absorption while maintaining safety and stability. Enhanced penetration refers to the increased flux of an API across the stratum corneum—the skin’s outermost layer—so that therapeutic concentrations reach the intended site of action, be that the epidermis, dermis, or systemic circulation depending on the product’s indication.

Topical drug development requires a nuanced understanding of the physicochemical interplay between the API, excipients, and the skin’s unique structure. At Dow Development Labs (DDL) in Petaluma, CA, development teams routinely encounter projects where the balance between efficacy and tolerability hinges on the ability to improve topical drug absorption without increasing irritation or compromising product stability. Whether supporting 505(b)(2) development or new chemical entities, the design of topical formulations is guided by a clear objective: to facilitate API penetration in a controlled, predictable manner compatible with regulatory and clinical requirements.

Ultimately, enhanced skin penetration is not an end in itself, but a means to achieving targeted drug delivery, dose sparing, and improved patient outcomes in topical therapies. Understanding what constitutes “enhanced” in a given program is the first step toward rational formulation design.

For further reading, see Improved Topical Drug Delivery: Role of Permeation Enhancers and from the National Institutes of Health.

Critical Factors That Influence Topical Drug Absorption

The ability of an API to traverse the skin is determined by a complex interplay of drug-specific, formulation-specific, and biological factors. To improve topical drug absorption, it is essential to systematically consider each of these:

• API Physicochemical Properties: Molecular weight, lipophilicity (Log P), ionization state (pKa), and solubility directly affect skin permeation. APIs with molecular weights <500 Da and balanced hydrophilic-lipophilic properties (Log P 1–3) are generally more permeable.
• Vehicle and Excipients: The formulation matrix (e.g., creams, gels, ointments, solutions) modulates drug release and skin partitioning. Excipients can act as solubilizers, wetting agents, or permeation enhancers, altering the rate and extent of absorption.
• Skin Condition and Site: Regional variation in skin thickness, hydration, and integrity (e.g., compromised barrier in atopic dermatitis) can substantially impact absorption. Preclinical and clinical models often account for these biological variables during formulation evaluation.
• Application Parameters: Dose applied, frequency, surface area, and occlusion (covering the application site) are critical during both in vitro and in vivo assessments of drug absorption.

For example, a topical corticosteroid cream formulated for the scalp must account for increased absorption through thinner skin and the need for a non-greasy, spreadable base. Conversely, a transdermal analgesic patch is designed for slow, sustained release through intact skin, prioritizing different formulation approaches. At Dow Development Labs, early-stage CMC and formulation planning integrates these factors to align with the intended use and regulatory pathway.

Best Practices to Improve Topical Drug Absorption During Formulation

Optimizing topical drug delivery is a multifaceted process. The following best practices are commonly used by formulation scientists to improve topical drug absorption:

1. API Characterization and Preformulation:
   • Conduct thorough preformulation studies to assess solubility, stability, and compatibility with excipients.
   • Screen polymorphic forms and salts for improved solubility and permeability profiles.
2. Vehicle Selection:
   • Choose a vehicle (e.g., emulsion, gel, ointment) that enhances drug release and facilitates partitioning into the stratum corneum.
3. Excipients and Functional Ingredients:
   • Incorporate excipients such as surfactants, solvents, or fatty acids known to disrupt or fluidize the stratum corneum lipids.
   • Use humectants (e.g., glycerin, propylene glycol) to hydrate the skin and transiently open barrier pathways.
4. Permeation Enhancer Selection:
   • Screen a range of permeation enhancers in vitro to identify candidates that increase flux without excessive irritation.
5. Formulation Optimization:
   • Employ Design of Experiments (DoE) to systematically vary formulation parameters and identify optimal compositions.
6. In Vitro Permeation Testing (IVPT):
   • Use human or animal skin models to assess drug permeation early and iteratively during development.

By integrating these practices, teams can streamline product development and mitigate risks, supporting timely progression through regulatory and clinical phases. DDL’s experienced scientists work closely with clients to tailor these approaches to the specific needs of each program.

Utilizing Permeation Enhancers: Opportunities and Limitations

Permeation enhancers are excipients or co-solvents added to topical formulations to increase API flux through the stratum corneum. They function by temporarily disrupting lipid bilayers, altering protein conformation, or increasing solubility of the API within the skin. Common permeation enhancers include ethanol, propylene glycol, oleic acid, and surfactants such as polysorbates. The judicious use of these agents may help improve topical drug absorption, particularly for APIs with suboptimal physicochemical properties.

Opportunities:

• May enable lower drug loading, reducing risk of irritation or adverse effects.
• Can facilitate delivery of poorly permeable APIs or higher molecular weight molecules (e.g., peptides in development programs).
• Allow for flexible formulation approaches, including the creation of microemulsions or liposomal systems for challenging compounds.

Limitations:

• Potential for increased skin irritation or sensitization, particularly with higher concentrations or repeated application.
• Regulatory scrutiny regarding safety—some enhancers have restricted use or require additional toxicological data.
• Variable efficacy depending on API structure and skin type; not all APIs respond to permeation enhancers equally.

For instance, ethanol and propylene glycol are frequently used in dermatology products for their ability to enhance penetration, but their concentrations must be carefully controlled to avoid drying or irritation. When formulating at Dow Development Labs, permeation enhancer choice is guided by a combination of historical data, regulatory precedent, and targeted in vitro testing to balance efficacy and safety.

Formulation Techniques for Maximizing Skin Penetration

Leveraging advanced formulation techniques can further improve topical drug absorption and overcome some limitations of traditional vehicles. Key approaches include:

• Microemulsions and Nanoemulsions: These systems offer increased solubilization of hydrophobic APIs and enhanced interfacial contact with the skin, leading to improved penetration. For example, nanoemulsified corticosteroid gels have shown higher bioavailability in comparative IVPT studies.
• Liposomal and Vesicular Systems: Encapsulation of APIs in lipid-based vesicles may facilitate transport across the stratum corneum by merging with skin lipids. This is particularly relevant for peptides and hydrophilic drugs.
• Supersaturated Formulations: Temporarily increasing API concentration above its solubility limit in the vehicle (“supersaturation”) can create a greater thermodynamic gradient, driving drug flux into the skin. Careful formulation is required to prevent crystallization over time.
• Hydrogel and Organogel Matrices: Hydrogels provide a hydrated environment that can enhance the dissolution of hydrophilic APIs and maintain skin moisture, supporting enhanced penetration.
• Occlusive Dressings: While not a formulation per se, using occlusion (e.g., patches, films) over the application site can increase skin hydration and permeability, often applied in transdermal systems.

The selection of these techniques is guided by API characteristics, target indication, and patient requirements. At DDL, these systems are explored as part of a comprehensive development plan, with a focus on scalability, manufacturability, and regulatory compatibility.

Analytical Methods for Assessing Topical Drug Absorption

Reliable, reproducible analytical methods are essential to quantify API delivery and support regulatory submissions. The most widely used tools in topical drug development include:

• In Vitro Permeation Testing (IVPT): Utilizes human or animal skin mounted in Franz diffusion cells to measure drug flux over time. IVPT is considered the gold standard for screening and comparative characterization.
• In Vivo Tape Stripping: Sequential removal of skin layers post-application quantifies drug concentration at different skin depths, providing insight into penetration and retention.
• Raman and Confocal Microscopy: Non-invasive imaging techniques enable visualization of API distribution within the stratum corneum and viable epidermis, supporting mechanism-of-action studies.
• Pharmacokinetic Studies: For transdermal and systemic delivery products, plasma drug levels in animal models or clinical subjects confirm systemic absorption and bioavailability.

At Dow Development Labs, analytical method development is aligned with regulatory expectations and tailored to each program’s stage—supporting preclinical screening, clinical supply release, and long-term stability studies. The integration of IVPT and advanced imaging helps de-risk formulation decisions early in development.

Addressing Formulation Challenges: Stability, Irritation, and Patient Compliance

Improving topical drug absorption is only valuable if the formulation maintains stability, is well-tolerated, and supports patient adherence. Key challenges include:

• Chemical and Physical Stability: High drug loadings, supersaturated systems, or aggressive permeation enhancers can increase the risk of crystallization, phase separation, or API degradation. Robust stability-indicating assays and accelerated studies are used to monitor these risks.
• Irritation and Sensitization: Enhanced penetration can increase exposure to both API and excipients, raising the risk of skin irritation. Preclinical (e.g., Draize) and early clinical safety assessments are critical. Formulation adjustments—such as lowering enhancer concentrations or adding emollients—can mitigate adverse effects.
• Patient Acceptability and Compliance: Greasiness, odor, residue, and ease of application are important factors affecting real-world use. Patient-centric design (e.g., non-staining, fast-absorbing gels for acne or psoriasis) helps optimize outcomes, as does packaging (e.g., pumps, tubes) that supports convenient dosing.

For example, a highly effective formulation that causes erythema or is cosmetically unattractive is unlikely to succeed in the clinic or market. At DDL, program teams work closely with sponsors to iterate on aesthetic and functional aspects, alongside technical optimization, to support successful development.

Integrating Best Practices in Topical Formulation Development: A Programmatic Approach

Successful topical drug development requires the coordinated application of scientific rigor, regulatory awareness, and practical manufacturing know-how. At Dow Development Labs, programs are structured to integrate the best practices described above into a phased, milestone-driven process that addresses:

• Strategic Planning: Early identification of key absorption challenges, formulation options, and regulatory considerations based on API profile and clinical objectives.
• Iterative Formulation Development: Systematic screening using DoE, IVPT, and compatibility studies to converge on optimal candidates.
• Risk Assessment: Ongoing evaluation of stability, safety, and manufacturability to anticipate and mitigate downstream issues.
• Cross-functional Collaboration: Close coordination among CMC, analytical, clinical, and regulatory teams to align development with program goals and timelines.
• Scalability and Tech Transfer: Early consideration of commercial feasibility, including raw material sourcing, process scalability, and packaging compatibility.

By embedding these principles into each stage of development, DDL helps sponsors navigate the complexities of topical drug delivery and improve topical drug absorption in a manner consistent with industry standards and regulatory expectations. Our team is committed to supporting programs from feasibility through clinical supply and beyond, acting as a collaborative partner for innovative topical and transdermal products.

Ready to advance your topical drug development program? Contact Dow Development Labs at 707-202-6965 to discuss how our formulation expertise and integrated services can help you improve topical drug absorption and achieve your project milestones.